Benign prostatic hyperplasia (BPH) is one of the most common urological diseases in aging men. Because of its long latency, BPH is a good target for prevention. The aim of the study has been to review the various options of treatment, currently available, in the field of phytotherapy. Watchful waiting, pharmacological therapy, and surgery are also helpful, depending on the severity of the disease. Although drug therapy (alpha1-blockers, 5alpha-reductase inhibitors) and surgery (prostatectomy, transurethral resection, etc.) seem to be most effective for patients with moderate-severe BPH, herbal medicines (i.e., Serenoa repens, Pygeum africanum, Urtica dioica) are also commonly used in patients with mild-moderate symptoms. On the basis of preclinical studies several mechanisms of action have been postulated, including 5alpha-reductase inhibition, alpha-adrenergic antagonism, dihydrotestosterone and estrogen receptor inhibition. Randomized clinical trials indicate significant efficacy in

What do we know about phytotherapy of benign prostatic hyperplasia? / Allkanjari, Olta; Vitalone, Annabella. - In: LIFE SCIENCES. - ISSN 0024-3205. - STAMPA. - 126:(2015), pp. 42-56. [10.1016/j.lfs.2015.01.023]

What do we know about phytotherapy of benign prostatic hyperplasia?

Olta Allkanjari;VITALONE, Annabella
2015

Abstract

Benign prostatic hyperplasia (BPH) is one of the most common urological diseases in aging men. Because of its long latency, BPH is a good target for prevention. The aim of the study has been to review the various options of treatment, currently available, in the field of phytotherapy. Watchful waiting, pharmacological therapy, and surgery are also helpful, depending on the severity of the disease. Although drug therapy (alpha1-blockers, 5alpha-reductase inhibitors) and surgery (prostatectomy, transurethral resection, etc.) seem to be most effective for patients with moderate-severe BPH, herbal medicines (i.e., Serenoa repens, Pygeum africanum, Urtica dioica) are also commonly used in patients with mild-moderate symptoms. On the basis of preclinical studies several mechanisms of action have been postulated, including 5alpha-reductase inhibition, alpha-adrenergic antagonism, dihydrotestosterone and estrogen receptor inhibition. Randomized clinical trials indicate significant efficacy in
2015
benign prostatic hyperplasia; clinical efficacy; finasteride; kaempferol; lycopene; palmitic acid; phytotherapy; review; rooperol; safety profile; saw palmetto; selenium; stigmasterol; tamsulosin; n-docosanol; β-Sitosterol
01 Pubblicazione su rivista::01a Articolo in rivista
What do we know about phytotherapy of benign prostatic hyperplasia? / Allkanjari, Olta; Vitalone, Annabella. - In: LIFE SCIENCES. - ISSN 0024-3205. - STAMPA. - 126:(2015), pp. 42-56. [10.1016/j.lfs.2015.01.023]
File allegati a questo prodotto
File Dimensione Formato  
Allkanjari_What-do_2015.pdf

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 415.85 kB
Formato Adobe PDF
415.85 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/780926
Citazioni
  • ???jsp.display-item.citation.pmc??? 29
  • Scopus 76
  • ???jsp.display-item.citation.isi??? 61
social impact